Vaccination against shigellosis: is it the path that is difficult or is it the difficult that is the path?

Microbes and Infection

Volumn 10, Issue 9, 2008, Pages 1057-1062

  Phalipon, Armelle ^a   Mulard, Laurence A ^a,b   Sansonetti, Philippe J ^a  

^a INSTITUT PASTEUR   (France)

^b Unité de Chimie Organique   (France)

Author keywords

Shigella; Shigellosis; Vaccine

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CARBOHYDRATE DERIVATIVE; GLYCOCONJUGATE; LIVE VACCINE; O ANTIGEN; POLYSACCHARIDE PROTEIN CONJUGATE; SHIGELLA VACCINE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBIOTIC THERAPY; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL METABOLISM; BACTERIAL TRANSMISSION; CLINICAL TRIAL; DELETION MUTANT; DISEASE SURVEILLANCE; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSPOT ASSAY; GENE DELETION; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOGENICITY; INCIDENCE; INFECTION PREVENTION; INFECTION RATE; INNATE IMMUNITY; INOCULATION; KNOCKOUT GENE; MOLECULAR MIMICRY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; SHIGELLA BOYDII; SHIGELLA DYSENTERIAE; SHIGELLA FLEXNERI; SHIGELLA SONNEI; SHIGELLOSIS; VACCINATION; VACCINE PRODUCTION;

DYSENTERY, BACILLARY; HUMANS; SHIGELLA; SHIGELLA VACCINES; VACCINATION; VACCINES, ATTENUATED; VACCINES, CONJUGATE; VACCINES, SYNTHETIC;

SHIGELLA;

EID: 53449085060     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2008.07.016     Document Type: Article

References (49)

1. Kotloff K.L., Winickoff J.P., Ivanoff B., Clemens J.D., Swerdlow D.L., Sansonetti P.J., Adak G.K., and Levine M.M. Global burden of Shigella infections: implication for vaccine development and implementation of control strategies. Bull. World Health Organ 77 (1999) 651-666
2. Kosek M., Bern C., and Guerrant R.L. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull. World Health Organ 81 (2003) 197-204
3. Von Seidlen L., Kim D.R., Ali M., Lee H., Wang X., Thiem V.D., Canh do G., Chaicumpa W., Agtini M.D., Hossain A., Bhutta Z.A., Mason C., Sethabutr O., Talukder K., Nair G.B., Deen J.L., Kotloff K., and Clemens J. A multicentre study of Shigella diarrhea in six Asian countries: disease burden, clinical manifestations, and microbiology. PloS Med 3 (2006) e353
4. Nato F., Phalipon A., Nguyen T.L., Diep T.T., Sansonetti P.J., and Germani Y. Dipstick for rapid diagnosis of Shigella flexneri 2a in stool. PLoS ONE 2 (2007) e361
5. Formal S.B., Oaks E.V., Olsen R.E., Wingfield-Eggleston M., Snoy P.J., and Cogan J.P. Effect of prior infection with Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei. J. Infect. Dis 164 (1991) 534-537
6. Lindberg A.A., Kärnell A., and Weintraub A. The lipopolysaccharide of Shigella bacteria as a virulence factor. Rev. Infect. Dis 13 (1991) S279-S284
7. Levine M.M., Kotloff K.L., Barry E.M., Pasetti M.F., and Sztein M.B. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat. Rev. Microbiol. 5 (2007) 540-553
8. Mel D.M., Gangarosa E.J., Radovanovic M.L., Arsic B.L., and Litvinjenko S. Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with Streptomycin-dependant Shigella strains. Bull. World Health Organ 45 (1971) 457-464
9. Phalipon A., and Sansonetti P.J. Shigella's ways of manipulating the host intestinal innate and adaptative immune system: a tool box for survival ?. Immunol. Cell. Biol. 85 (2007) 119-129
10. Kärnell A., Li A., Zhao C.R., Karlsson K., Nguyen B.M., and Lindberg A.A. Safety and immunogenicity study of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers. Vaccine 13 (1995) 88-89
11. Li A., Cam P.D., Islam D., Minh N.B., Huan P.T., Rong Z.C., Karlsson K., Lindberg G., and Lindberg A.A. Immune responses in Vietnamese children after a single dose of the auxotrophic, live Shigella Y vaccine strain SFL124. J. Infect 28 (1994) 11-23
12. Noriega F.R., Wang J.Y., Losonsky G., Maneval D.R., Hone F.M., and Levine M.M. Engineered DguaBA, DvirG Shigella flexneri 2a strain CVD1205: construction, safety, immunogenicity and protective efficacy as a mucosal vaccine. Infect. Immun. 64 (1994) 3055-3061
13. Nassif X., Mazert M.C., Mounier J., and Sansonetti P.J. Evaluation with an iuc::Tn10 mutant of the role of aerobactin production in the virulence of Shigella flexneri. Infect. Immun. 55 (1987) 1963-1969
14. Bernardini M.L., Mounier J., d'Hauteville H., Coquis-Rondon M., and Sansonetti P.J. Identification of icsA, a plasmid locus of Shigella flexneri that governs bacterial intra- and intercellular spread through interaction with F-actin. Proc. Natl. Acad. Sci. USA 86 (1989) 3867-3871
15. Sansonetti P.J., and Arondel J. Construction and evaluation of a double mutant of Shigella flexneri as a candidate for oral vaccination against shigellosis. Vaccine 7 (1991) 443-450
16. Coster T.S., Hoge C.W., VanDeVerg L.L., Hartman A.B., Oaks E.V., Venkatesan M.M., Cohen D., Robin G., Fontaine-Thompson A., Sansonetti P.J., and Hale T.L. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect. Immun. 67 (1999) 3437-3443
17. Katz D.E., Coster T.S., Wolf M.K., Trespalacios F.C., Cohen D., Robins G., Hartman A.B., Venkatesan M.M., Taylor D.N., and Hale T.L. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organismes in North American volunteers. Infect. Immun. 72 (2004) 923-930
18. Kotloff K.L., Taylor D.N., Sztein M.B., Wasserman S.S., Losonsky G.A., Nataro J.P., Venkatesan M., Hartman A., Picking W.D., Katz D.E., Campbell J.D., Levine M.M., and Hale T.L. Phase I evaluation of a virG deleted Shigella sonnei live, attenuated vaccine (Strain WRSS1) in healthy adult volunteers. Infect. Immun. 70 (2002) 2016-2021
19. Noriega F.R., Liao F.M., Maneval D.R., Ren S., Formal S.B., and Levine M.M. Strategy for cross protection among Shigella flexneri serotypes. Infect. Immun. 67 (1999) 782-788
20. Kotloff K.L., Pasetti M.F., Barry E.M., Nataro J.P., Wasserman S.S., Sztein M.B., Picking W.D., and Levine M.M. Deletion of the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing Guanine auxotrophy in a phase I trial of CVD1204 and CVD1208. J. Infect. Dis. 190 (2004) 1745-1754
21. Kotloff K.L., Simon J.K., Pasetti M.F., Sztein M.B., Wooden S.L., Livio S., Nataro J.P., Blackwelder W.C., Barry E.M., Picking W., and Levine M.M. Safety and immunogenicity of CVD 12058, a live, oral D gna BA D sen D set Shigella flexneri 2a vaccine grown on animal free media. Human Vaccine 3 (2007) 268-275
22. Arbibe L., Kim D.W., Batsche E., Pedron T., Mateescu B., Muchardt C., Parsot C., and Sansonetti P.J. An injected bacterial effector targets chromatin access for transcription factor NF-kappaB to alter transcription of host genes involved in immune responses. Nat. Immunol. 8 1 (2007) 47-56
23. Jennings H. Further approaches for optimizing polysaccharide-protein conjugate vaccines for prevention of invasive bacterial disease. J. Infect. Dis. 165 (1992) S156-S159
24. Ada G., and Isaacs D. Carbohydrate-protein conjugate vaccines. Clin. Microbiol. Infect. 9 (2003) 79-85
25. Lockhart S. Conjugate vaccines. Expert Rev. Vaccines 2 (2003) 633-648
26. Taylor D.N., Trofa A.C., Sadoff J., Chu C., Bryla D., Shiloach J., Cohen D., Ashkenazi S., Levman Y., Egan W., Schneerson R., and Robbins J.B. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect. Immun 61 (1993) 3678-3687
27. Passwell J.H., Harleve E., Ashkenazi S., Chu C., Miron D., Ramon R., Farsan N., Shiloach J., Bryla D.A., Majadly F., Robertson R., Robbins J.B., and Shchneerson R. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect. Immun. 69 (2001) 1351-1357
28. Passwell J.H., Ashkenazi S., Harlev E., Miron D., Ramon R., Farzam N., Lerner-Geva L., Levi Y., Chu C., Shiloach J., Robbins J.B., and Schneerson R. Israel Shigella Study Group. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children. Pediatr. Infect. Dis. J. 22 (2003) 701-706
29. Cohen D., Ashkenazi S., Green M.S., Gdalevitch M., Robin G., Slepon R., Yavzoni M., Orr N., Block C., Ashkenazi I., Shemer J., Taylor D.N., Hale T.L., Sadoff J.C., Pavliovka D., Schneerson R., and Robbins J.B. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 349 (1997) 155-159
30. Goebel W.F. Studies on antibacterial immunity induced by artificial antigens. II. Immunity of experimental pneumococcal infection with antigens containing saccharides of synthetic origin. J. Exp. Med. 72 (1940) 33-48
31. Pozsgay V. Oligosaccharide-protein conjugates as vaccine candidates against bacteria. Adv. Carbohydr. Chem. Biochem. 56 (2000) 153-199
32. Pozsgay V., Kubler-Kielb J., Schneerson R., and Robbins J.B. Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice. Proc. Natl. Acad. Sci. USA 104 36 (2007) 14478-14482
33. Jansen W.T.M., and Snippe H. Short-chain oligosaccharide protein conjugates as experimental pneumococcal vaccines. Indian J. Med. Res. 119 Suppl (2004) 7-12
34. Johnson M.A., and Pinto B.M. Molecular mimicry of carbohydrates by peptides. Aust. J. Chem. 55 (2002) 13-25
35. Clément M.J., Fortuné A., Phalipon A., Marcel-Peyre V., Simenel C., Imberty A., Delepierre M., and Mulard L.A. Toward a better understanding of the molecular basis of polysaccharide mimicry by oligosaccharides and peptides: the example of Shigella flexneri 5a. J. Biol. Chem. 281 (2006) 2317-2332
36. Gulati S., Ngampasutadol J., Yamasaki R., McQuillen D.P., and Rice P.A. Strategies for mimicking Neisserial saccharide epitopes as vaccines. Int. Rev. Immunol. 20 (2001) 229-250
37. Phalipon A., Folgori A., Arondel J., Sgaramella G., Fortugno P., Cortese R., Sansonetti P.J., and Felici F. Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics. Eur. J. Immunol. 27 10 (1997) 2620-2625
38. Pavliak V., Nashed E., Pozsgay V., Kovac P., Karpas A., Chu C., Schneerson R., Robbins J.B., and Glaudemans C.P.J. Binding of the O-antigen of Shigella dysenteriae type 1 and 26 related synthetic fragments to a monoclonal IgM antibody. J. Biol. Chem. 268 (1993) 25797-25802
39. Pozsgay V., Chu C., Pannell L., Wolfe J., Robbins J.B., and Schneerson R. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc. Natl. Acad. Sci. USA 96 (1999) 5194-5197
40. Phalipon A., Costachel C., Grandjean C., Thuizat A., Guerriero C., Tanguy M., Nato F., Vulliez Le Normand B., Bélot F., Wright K., Marcel Peyre V., Sansonetti P.J., and Mulard L.A. Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine. J. Immunol. 176 (2006) 1686-1694
41. Mulard L.A., Costachel C., and Sansonetti P.J. Synthesis of the methyl glycosides of a di- and two trisaccharide fragments specific for the Shigella flexneri serotype 2a O-antigen. J. Carbohydr. Chem. 19 (2000) 849-877
42. Costachel C., Sansonetti P.J., and Mulard L.A. Linear synthesis of the methyl glycosides of tetra- and pentasaccharide fragments specific for the Shigella flexneri serotype 2a O-antigen. J. Carbohydr. Chem. 19 (2000) 1131-1150
43. Segat-Dioury F., and Mulard L.A. Convergent synthesis of the methyl glycosides of a tetra- and a pentasaccharide fragment of the Shigella flexneri 2a O-specific polysaccharide. Tetrahedron: Asymm. 13 (2002) 2211-2222
44. Bélot F., Costachel C., Wright K., Phalipon A., and Mulard L.A. Synthesis of the methyl glycoside of a branched octasaccharide fragment specific for the Shigella flexneri serotype 2a O-antigen. Tetrahedron Lett. 43 (2002) 8215-8218
45. Bélot F., Wright K., Costachel C., Phalipon A., and Mulard L.A. Blockwise approach to fragments of the O-specific polysaccharide of Shigella flexneri serotype 2a: convergent Synthesis of a decasaccharide representative of a dimer of the branched repeating unit. J. Org. Chem. 69 (2004) 1060-1074
46. Mulard L.A., and Guerreiro C. Total synthesis of a tetra- and two pentasaccharide fragments of the O-specific polysaccharide of Shigella flexneri serotype 2a. Tetrahedron 60 (2004) 2475-2488
47. Bélot F., Guerreiro C., Baleux F., and Mulard L.A. Synthesis of two linear PADRE-conjugates bearing a deca- or pentadecasaccharide B epitope as potential synthetic vaccines against Shigella flexneri serotype 2a infection. Chemistry 11 (2005) 1625-1635
48. Wright K., Guerriero C., Laurent I., Baleux F., and Mulard L.A. Preparation of synthetic glycoconjugates as potential vaccines against Shigella flexneri serotype 2a disease. Org. Biomol. Chem. 2 (2004) 1518-1527
49. Phalipon A., and Mulard L.A. From epitope characterization to the design of semi-synthetic glycoconjugate vaccines against Shigella flexneri 2a infection. In: Roy R. (Ed). Symposium on Carbohydrate-based Vaccines (2008), American Chemical Society (ACS) books 105-136